In the last trading session, 1,252,191 Agile Therapeutics, Inc. (NASDAQ:AGRX) shares changed hands as the company’s beta touched 1.1. With the company’s per share price at $1.96 changed hands at -$0.09 or -0.04% during last session, the market valuation stood at $171.75 Million. AGRX’s last price was a discount, traded about -98.47% off its 52-week high of $3.89. The share price had its 52-week low at $1.75, which suggests the last value was 10.71% up since then. When we look at Agile Therapeutics, Inc.’s average trading volume, we note the 10-day average is 2.55 Million shares, with the 3-month average coming to 1.63 Million.
Analysts gave the Agile Therapeutics, Inc. (AGRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.6. If we narrow down to specifics, the data shows that none out of 5 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, none recommended AGRX as a Hold, 5 felt it is a Buy and none rated the stock as Underweight. Agile Therapeutics, Inc.’s EPS for the current quarter is expected to be -$0.21.
Agile Therapeutics, Inc. (NASDAQ:AGRX) trade information
Although AGRX has turned red as seen at the end of in last trading. With action -4.39%, the performance over the past five days has been red. The jump to weekly highs of $2.25 on Wednesday, Mar 24 added 12.89% to the stock’s daily price. The company’s shares are showing year-to-date downside of -0.32%, with the 5-day performance at -0.02% in the red. However, in the 30-day time frame, Agile Therapeutics, Inc. (NASDAQ:AGRX) is -0.32% down. Looking at the short shares, we see there were 3.91 Million shares sold at short interest cover period of 2.4 days.
The consensus price target for the stock as assigned by Wall Street analysts is $7.8, meaning bulls need an upside of 297.96% from its current market value. According to analyst projections, AGRX’s forecast low is $6 with $10 as the target high. To hit the forecast high, the stock’s price needs a +410.2% upsurge from its current level, while the stock would need to tank 206.12% for it to hit the projected low.
Agile Therapeutics, Inc. (AGRX) estimates and forecasts
Data shows that the Agile Therapeutics, Inc. share is not performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value dive -31.94% over the past 6 months, a -1.64% in annual growth rate that is considerably lower than the industry average of -0.5%. But despite this, analysts have looked to lower expectations by downgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Agile Therapeutics, Inc. will drop -110%, while the growth in revenue is estimated to hit -41.7% for the next quarter. Year-over-year growth is forecast to reach 3822.6% up from the last financial year.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 15%. The 2021 estimates are for Agile Therapeutics, Inc. earnings to decrease by -62.7%, but the outlook for the next 5-year period is at 0% per year.
Agile Therapeutics, Inc. (NASDAQ:AGRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.98% of Agile Therapeutics, Inc. shares while 49.81% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 50.3%. There are 107 institutions holding the Agile Therapeutics, Inc. stock share, with Perceptive Advisors Llc the top institutional holder. As of Dec 30, 2020, the company held 18.17% of the shares, roughly 15.92 Million AGRX shares worth $45.69 Million.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 5.85% or 5.12 Million shares worth $14.7 Million as of Dec 30, 2020.
Among Mutual Funds, the top two as of Dec 30, 2020 were Vanguard Total Stock Market Index Fund and John Hancock Small Cap Core Fd. With 2763477 shares estimated at $7.93 Million under it, the former controlled 3.15% of total outstanding shares. On the other hand, John Hancock Small Cap Core Fd held about 2.07% of the shares, roughly 1.82 Million shares worth around $5.12 Million.